Matthew E. Butchbach, Ph.D.
Affiliations: | 2003 | Ohio State University, Columbus, Columbus, OH |
Area:
Biochemistry, Neuroscience Biology, Molecular Biology, Cell BiologyGoogle:
"Matthew Butchbach"Mean distance: 35622
Parents
Sign in to add mentor| Chien-liang G. Lin | grad student | 2003 | Ohio State | |
| (Regulation of glutamate transport by GTRAP3-18 and by lipid rafts.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Edwards JD, Butchbach ME. (2016) Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy. Journal of Neuromuscular Diseases. 3: 511-515 |
| Rossi SL, Lumpkin CJ, Harris AW, et al. (2016) Identification of early gene expression changes in primary cultured neurons treated with topoisomerase I poisons. Biochemical and Biophysical Research Communications |
| Butchbach ME, Lumpkin CJ, Harris AW, et al. (2016) Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Experimental Neurology |
| Harris AW, Butchbach ME. (2015) The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy. Neuromuscular Disorders : Nmd. 25: 699-705 |
| Mack SG, Cook DJ, Dhurjati P, et al. (2014) Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy. Plos One. 9: e115473 |
| Maeda M, Harris AW, Kingham BF, et al. (2014) Transcriptome profiling of spinal muscular atrophy motor neurons derived from mouse embryonic stem cells. Plos One. 9: e106818 |
| Butchbach ME, Singh J, Thorsteinsdóttir M, et al. (2010) Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Human Molecular Genetics. 19: 454-67 |
| Mattis VB, Butchbach ME, Lorson CL. (2008) Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy. Journal of Neuroscience Methods. 175: 36-43 |
| Thurmond J, Butchbach ME, Palomo M, et al. (2008) Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Journal of Medicinal Chemistry. 51: 449-69 |
| Gabanella F, Butchbach ME, Saieva L, et al. (2007) Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. Plos One. 2: e921 |